Filing Analysis
Lifeward Ltd. announced several changes to its Board of Directors, including the appointment of three new Class III Directors and the resignation of Nadav Kidron. The company stated that Mr. Kidron's departure was not due to any disagreement with the company's operations or policies.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- On August 14, 2026, Yonason Greenwald and Haggai Zamir were appointed as Class III Directors.
- Yonason Greenwald joined the Audit, Compensation, and Nominating and Corporate Governance Committees.
- On August 20, 2026, Avraham Gabay was appointed as a Class III Director and Chair of the Board.
- Nadav Kidron resigned from the Board effective August 20, 2026.
- The company explicitly stated Kidron's departure was not due to any disagreement regarding operations, policies, or practices.
Lifeward Ltd. announced a significant leadership overhaul involving the simultaneous resignation of three Board members and the departure of its Chief Financial Officer (CFO). While the company states the board departures were not due to disagreements, the rapid exit of key governance and financial leadership is highly unusual.
🚩 Red Flags
- Simultaneous resignation of three Board members (governance instability).
- Departure of the Chief Financial Officer (CFO) within a short window of board changes.
- Multiple leadership departures in a single 8-K filing (escalator for severity).
📋 Key Facts
- Three directors—Robert J. Marshall, Jr., Michael Swinford, and William Mark Sigsbee—resigned effective August 13, 2026.
- CFO Almog Adar will step down from his role on September 30, 2026.
- The company entered into a separation agreement with CFO Almog Adar on August 10, 2026.
- The departure of the CFO is being treated as a 'termination without cause' for benefit purposes.
- The company also furnished Q2 2026 financial results via press release.
Lifeward Ltd. entered into a significant securities purchase agreement with Oramed Pharmaceuticals Inc. and other investors to issue $11.16 million in senior secured convertible notes and accompanying warrants. The deal includes complex performance-based tranches and potential dilution via conversion features.
🚩 Red Flags
- High default interest rate (8.0% to 15.0%) indicates significant risk to the company's capital structure.
- Potential for massive dilution due to senior secured convertible notes and warrants at a $5.40 conversion price.
- The 'Second Notes' are contingent on aggressive growth targets (150% increase in sales) or high stock price, suggesting liquidity is tied to performance milestones.
- Senior secured status of the debt places these investors ahead of existing equity holders in liquidation.
📋 Key Facts
- Total aggregate principal amount of new notes: $11,160,000 ($5.58M Initial + $5.58M Second Notes).
- Initial Note transaction closed on July 6, 2026.
- Second Notes funding is contingent upon either a 150% increase in ReWalk Unit Sales or the stock price hitting $13.80 for 10 consecutive trading days.
- Notes carry an 8.0% interest rate, which jumps to 15.0% upon an event of default.
- Initial conversion price set at $5.40 per share; warrants also have a $5.40 exercise price.
- Warrants are exercisable for up to 100% of the shares convertible under the notes and expire in five years.
- Includes an exchange cap of 19.99% on total shares issued via conversion/exercise without shareholder approval.
Lifeward Ltd. announced that Joseph Turk will step down as Chairperson of the Board effective December 31, 2025. Robert J. Marshall Jr. has been appointed to succeed him as Chairperson starting January 1, 2026.
📋 Key Facts
- Joseph Turk is stepping down from the Board and his role as Chairperson on December 31, 2025.
- The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
- Robert J. Marshall Jr. will be appointed as the new Chairperson of the Board effective January 1, 2026.
Lifeward Ltd. entered into a $3.0 million secured promissory note with Oramed Ltd., featuring a high 15% annual interest rate and conversion rights at $0.45 per share. The filing also includes the announcement of Q3 2025 financial results.
🚩 Red Flags
- High interest rate (15%) suggests urgent need for capital or high perceived risk by the lender.
- Loan is secured by a lien on cash, reducing liquidity available for operations.
- Convertible feature at $0.45 per share may lead to significant dilution for existing shareholders.
- Short maturity date (May 2026) creates near-term refinancing risk.
📋 Key Facts
- Entered into a Secured Promissory Note with Oramed Ltd. on November 14, 2025.
- Principal amount: $3.0 million.
- Interest rate: 15% per annum.
- Maturity date: May 14, 2026 (approx. 6 months).
- Security: The loan is secured by a lien on the Company's cash.
- Conversion price: $0.45 per ordinary share.
- Ownership cap: Oramed conversion subject to a 4.99% beneficial ownership limitation.
- Termination fee: $500,000 under certain circumstances.
Lifeward Ltd. released preliminary financial results for the quarter ended September 30, 2025, reporting approximately $6.2 million in revenue against operating expenses of $5.8M–$5.9M. The company reported a critically low cash position of approximately $2.0 million.
🚩 Red Flags
- Critically low liquidity: Cash balance of $2.0M is very low relative to quarterly operating expenses (~$5.8M-$5.9M), suggesting a potential cash runway of less than one quarter.
- Narrow operating margins: Preliminary revenue and expenses are closely aligned, leaving minimal buffer for working capital needs.
📋 Key Facts
- Preliminary revenue for Q3 2025: ~$6.2 million.
- Preliminary U.S. GAAP operating expenses: ~$5.8 million to $5.9 million.
- Cash and cash equivalents as of Sept 30, 2025: ~$2.0 million.
- Unaudited results provided under Item 2.02.
Lifeward Ltd. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2025. The filing includes a press release and notification of a conference call to discuss the quarterly performance.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) regarding financial results.
- A conference call was scheduled for August 14, 2025, at 8:30 a.m. EDT to discuss the results.
Lifeward Ltd. announced the appointment of Almog Adar as Chief Financial Officer (CFO) and principal financial officer, effective August 1, 2025. Mr. Adar is an internal promotion from his previous role as Vice President of Finance and Chief Accounting Officer.
🚩 Red Flags
- The appointment includes significant retention payments and accelerated vesting in the event of a Change of Control, which can be used as 'golden parachute' incentives.
📋 Key Facts
- Almog Adar appointed CFO and principal financial officer, effective August 1, 2025.
- Mr. Adar previously served as VP of Finance and CAO since March 2022; he will continue to serve as the Company's principal accounting officer.
- Annual base salary set at $315,000 with a performance bonus up to 35% of base salary.
- Retention package includes an $80,000 payment in two equal installments through Dec 31, 2025.
- Grant of 225,000 ordinary shares under the 2025 Incentive Compensation Plan, vesting over four years.
- Severance provisions include 6 months of salary/benefits for termination without cause; increases to 12 months if occurring near a Change of Control.
Lifeward Ltd. received a deficiency notice from Nasdaq because its closing bid price has been below $1.00 for the last 30 consecutive business days. The company has until February 2, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Failure to meet minimum bid price requirement for continued listing on Nasdaq Capital Market.
- Risk of delisting if compliance is not achieved within the 180-day window or subsequent extension.
📋 Key Facts
- Received Bid Price Letter from Nasdaq on August 5, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding minimum $1.00 bid price.
- The company has a 180-day compliance period ending February 2, 2026.
- A second 180-day extension may be available if certain market value and notification requirements are met.
- Current status: The shares remain listed and trading is not currently affected.
Lifeward Ltd. held its 2025 Annual Meeting of Shareholders on August 1, 2025, where shareholders approved the 2025 Incentive Compensation Plan and several director re-elections. Notably, Proposal 5 regarding equity compensation for a board member's consulting services failed to receive requisite support.
🚩 Red Flags
- Shareholder rejection of Proposal 5 regarding equity compensation for a board member's consulting services (811,866 For vs 993,112 Against).
- High level of 'Broker Non-Votes' across all proposals (~3.4M shares), suggesting significant institutional or non-participating shareholder presence.
📋 Key Facts
- Annual Meeting held on August 1, 2025.
- Quorum consisted of 5,223,471 ordinary shares (~45.0% of outstanding shares).
- Shareholders approved the Lifeward Ltd. 2025 Incentive Compensation Plan (Proposal 4).
- Directors Mark Grant, Dr. John William Poduska, and Randel E. Richner were re-elected.
- Kost Forer Gabbay & Kasierer (Ernst & Young Global) was reappointed as independent auditor for the year ending Dec 31, 2025.
- Proposal 5 (equity compensation to Randel E. Richner via Richner Consultants, LLC) failed to pass.
Lifeward Ltd. completed a best efforts public offering of 4,000,000 ordinary shares and 4,000,000 warrants at a combined price of $0.65 per unit. The offering is intended to raise approximately $2.0 million in net proceeds for working capital and commercial efforts.
🚩 Red Flags
- Significant dilution: The issuance of 4 million shares plus 4 million warrants represents substantial potential dilution for existing shareholders.
- Low offering price: $0.65 per unit is characteristic of micro-cap financing often used to address immediate liquidity needs.
- High cost of capital: Total fees (cash and warrants) represent a significant portion of the gross proceeds.
📋 Key Facts
- Offered 4,000,000 ordinary shares and 4,000,000 warrants at $0.65 per unit (combined).
- Warrants are immediately exercisable at an exercise price of $0.65.
- Net proceeds expected to be approximately $2.0 million after fees and expenses.
- Placement Agent is H.C. Wainwright & Co., LLC, receiving a 7% cash fee and 1% management fee.
- The company issued Placement Agent Warrants for 240,000 shares at an exercise price of $0.8125 (125% of the offering price).
- Includes a 30-day standstill on issuing new securities and a one-year prohibition on variable rate transactions.
Lifeward Ltd. announced changes to its Board of Directors, including the appointment of Mark Grant as a Class II director and the resignation of Co-CEO Larry Jasinski from the Board effective June 30, 2025.
🚩 Red Flags
- Co-CEO stepping down from the Board (though remaining as Co-CEO in an advisory capacity) can sometimes signal internal restructuring or shifts in governance.
📋 Key Facts
- Mark Grant appointed as Class II Director, effective June 15, 2025; he also serves as President and Co-CEO.
- Larry Jasinski to resign from the Board of Directors effective June 30, 2025.
- Jasinski will continue as Co-CEO until June 30, 2025, then transition to an advisory role through year-end 2025.
- The Company's Annual Meeting of Shareholders is scheduled for August 1, 2025.
Lifeward Ltd. announced the resignation of its Chief Financial Officer and Principal Financial Officer, Michael Lawless, effective June 27, 2025. The company stated the departure is for personal reasons and not due to any disagreement regarding financial operations or accounting practices.
🚩 Red Flags
- Sudden departure of a key executive (CFO/Principal Financial Officer) can create temporary administrative instability during transition periods.
📋 Key Facts
- Michael Lawless resigned as CFO and Principal Financial Officer on June 2, 2025.
- The resignation is effective June 27, 2025, or earlier by mutual agreement.
- The company explicitly stated the departure is for personal reasons and not related to any disagreements with the company or its independent auditors.
Lifeward Ltd. announced the appointment of Mark Grant as President and CEO, effective June 2, 2025. The transition includes a period of co-leadership with current CEO Larry Jasinski until July 1, 2025.
🚩 Red Flags
- Management transition period involves a co-CEO structure which can sometimes indicate internal friction or lack of immediate succession readiness, though here it is framed as a 'smooth leadership transition'.
📋 Key Facts
- Mark Grant appointed President and CEO, effective June 2, 2025.
- Co-CEO transition period: Mark Grant and Larry Jasinski to serve as Co-CEOs from June 2 to June 30, 2025.
- Grant will become sole CEO on July 1, 2025.
- Annual base salary for Grant is $435,000 with a performance bonus up to 70%.
- Inducement grant of 400,000 Ordinary Shares (options) vesting in four equal annual installments starting June 2, 2026.
- Grant brings significant experience from Medtronic plc, where he was VP for the Americas Region.
Lifeward Ltd. filed an 8-K to furnish its quarterly financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release and details the scheduled conference call for investors.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: First quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) containing financial results.
- A conference call to discuss the results was scheduled for May 15, 2025, at 8:30 a.m. EDT.
Lifeward Ltd. announced the U.S. national launch of its ReWalk 7 Personal Exoskeleton via a press release on April 15, 2025.
📋 Key Facts
- Company issued a press release regarding the U.S. national launch of the ReWalk 7 Personal Exoskeleton.
- The announcement occurred on April 15, 2025.
- The filing is categorized under Item 8.01 (Other Events).
Lifeward Ltd. reported preliminary Q1 2025 results showing an operating loss, with revenue of ~$5.0M against expected expenses of $6.5M–$6.7M. Additionally, the company announced the termination of its Chief Sales Officer without cause, effective May 30, 2025.
🚩 Red Flags
- Negative operating margin: Preliminary results indicate an expected quarterly loss of $1.5M to $1.7M.
- Executive turnover: Departure of the Chief Sales Officer during a period of reported losses.
📋 Key Facts
- Preliminary Q1 2025 revenue: approximately $5.0 million.
- Preliminary Q1 2025 U.S. GAAP operating expenses: expected range of $6.5 million to $6.7 million.
- Chief Sales Officer Charles Remsberg will depart effective May 30, 2025.
- Departure of CSO is a termination without cause; severance benefits will be paid per his August 11, 2023 agreement.
Lifeward Ltd. entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to facilitate the potential sale of ordinary shares up to an aggregate price of $5,488,800.
🚩 Red Flags
- Potential for immediate share dilution as the company can sell shares at market prices on an ongoing basis.
- ATM offerings are often used by micro-cap companies to raise working capital, which can signal a need for cash to fund operations.
📋 Key Facts
- Entered into ATM Agreement with H.C. Wainwright & Co., LLC on March 7, 2025.
- Maximum aggregate offering price: $5,488,800.
- Commission to agent (Wainwright): 3.0% of gross proceeds.
- Shares will be issued under a previously effective S-3 shelf registration statement (File No. 333-263984).
- The company is not obligated to sell any shares under the agreement.
Lifeward Ltd. filed an 8-K to announce the release of its financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Financial results for Q4 and FY 2024 were released on March 7, 2025.
- The company scheduled a conference call to discuss the results for March 7, 2025, at 8:30 a.m. EDT.
- An archived webcast of the discussion is available via the company's website and a provided media link.
Lifeward Ltd. announced the departure of its CEO, Larry Jasinski, effective by the end of Q2 2025, alongside preliminary FY2024 financial results showing significant operating losses.
🚩 Red Flags
- CEO departure (Larry Jasinski) announced alongside significant operating losses.
- Operating expenses ($33.4M) exceed revenue ($25.7M), indicating a net loss for the period.
- Presence of $5.7 million in restructuring and impairment expenses suggests ongoing operational adjustments or asset write-downs.
📋 Key Facts
- Preliminary FY2024 revenue: approximately $25.7 million.
- Preliminary FY2024 U.S. GAAP operating expenses: approximately $33.4 million.
- Includes ~$5.7 million in restructuring and impairment expenses.
- CEO Larry Jasinski to step down as CEO and Board member by the end of Q2 2025.
- Departure is treated as a termination without cause.
- The company will enter into a separation agreement with the departing CEO.
Lifeward Ltd. has cancelled its Extraordinary General Meeting of Shareholders scheduled for January 13, 2025. The company is also withdrawing all proposals previously set forth in its Definitive Proxy Statement filed on November 25, 2024.
🚩 Red Flags
- Abrupt cancellation of a scheduled shareholder meeting and withdrawal of proxy proposals suggests internal disagreement or failure to reach consensus on critical corporate actions.
📋 Key Facts
- Extraordinary General Meeting (EGM) scheduled for Jan 13, 2025, has been cancelled.
- The company is withdrawing all proposals from the Definitive Proxy Statement filed on Nov 25, 2024.
- Filing date: January 13, 2025.
Lifeward Ltd. filed an 8-K/A (Amendment No. 1) to correct clerical errors in the exhibits of its original January 8, 2025 filing. The amendment replaces Exhibit 4.1 and Exhibit 4.2 due to inadvertent filing of incorrect documents during the Edgarization process.
🚩 Red Flags
- None identified; this is a corrective administrative filing.
📋 Key Facts
- Filing is an Amendment (Form 8-K/A) to an original report filed on January 8, 2025.
- The purpose is solely to replace Exhibit 4.1 (Form of Ordinary Warrant) and Exhibit 4.2 (Form of Placement Agent Warrant).
- The company explicitly states that the amendment does not change any information previously disclosed in the Original Filing regarding Items 1.01, 3.02, or 8.01.
- The filing was signed by CFO Mike Lawless on January 8, 2025.
Lifeward Ltd. entered into a registered direct offering and private placement of 1,818,183 ordinary shares and warrants for approximately $5.0 million in gross proceeds. The funds are intended for working capital and commercial efforts.
🚩 Red Flags
- Potential dilution from the issuance of 1.8M+ shares and corresponding warrants.
- Warrant overhang: The issuance of warrants equal to the number of shares issued can create significant selling pressure upon exercise.
- Reliance on external financing for working capital suggests limited organic cash flow.
📋 Key Facts
- Offering size: Approximately $5.0 million in gross proceeds.
- Securities issued: 1,818,183 ordinary shares at $2.75 per share and 1,818,183 ordinary warrants with an exercise price of $2.75.
- Warrant terms: Ordinary warrants are exercisable for three years; Placement Agent Warrants have an exercise price of $3.4375 (125% of offering price).
- Placement Agent: H.C. Wainwright & Co., LLC received a 7.0% cash fee and 1.0% management fee on gross proceeds.
- Lock-up/Restriction: 30-day restriction on issuing new equity; 1-year restriction on issuing debt or equity with floating conversion prices (anti-death spiral provisions).
- Registration requirement: Company must file a registration statement for the resale of shares underlying the warrants within 30 days.
Lifeward Ltd. filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2024. The filing includes a press release and notice of a conference call to discuss the earnings.
📋 Key Facts
- Reported date: November 12, 2024
- Reporting period: Third quarter ended September 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- A conference call was scheduled for November 12, 2024, at 8:30 a.m. EDT to discuss the results.
Lifeward Ltd. announced the expansion of its Board of Directors and the appointment of Robert J. Marshall Jr. as a new director and Chair of the Audit Committee, effective November 2, 2024.
📋 Key Facts
- Board expanded from six to seven directors.
- Robert J. Marshall Jr. appointed as Class III director, serving until the 2026 annual meeting.
- Mr. Marshall will serve as Chair of the Audit Committee.
- Mr. Marshall previously served as CFO and Treasurer at Lantheus Holdings, Inc.
- Compensation for Mr. Marshall will follow standard non-employee director compensation disclosed in the July 29, 2024 proxy statement.
ReWalk Robotics Ltd. held its 2024 Annual Meeting of Shareholders on September 4, 2024. While several key proposals passed—including director re-elections and a name change to 'Lifeward Ltd.'—the majority of shareholder compensation and incentive plans were rejected by voters.
🚩 Red Flags
- Significant shareholder rejection of executive compensation and incentive plans (Proposals 3, 4, 5, 6, and 9).
- High level of 'Against' votes on CEO-related equity grants and variable compensation structures.
- Potential misalignment between management incentives and shareholder interests.
📋 Key Facts
- The company held its Annual Meeting on September 4, 2024, with a quorum of 48.25% (4,206,883 shares).
- Proposal No. 2 was approved to change the Company's name to 'Lifeward Ltd.'
- Directors Hadar Levy and Joseph Turk were re-elected to the Board.
- The reappointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as independent auditors was approved.
- Shareholders rejected Proposal 3 (2024 Incentive Compensation Plan), Proposal 4 (Double compensation for Chairperson), Proposal 5 (RSU grant to CEO Larry Jasinski), and Proposal 6 (Changes to CEO variable compensation).
- Jeff Dykan retired from the Board effective September 4, 2024; Joseph Turk was appointed as new Chairperson.
ReWalk Robotics Ltd. filed an 8-K to furnish its second quarter financial results for the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of Q2 2024 financial results.
- Results were announced via press release on August 15, 2024.
- A conference call was scheduled for August 15, 2024, at 8:30 a.m. EDT to discuss the results.
ReWalk Robotics Ltd. announced the retirement of Board Chairperson Jeff Dykan, who will not stand for reelection at the 2024 Annual General Meeting. The company has appointed Joseph Turk to succeed him as chairperson effective at the meeting.
🚩 Red Flags
- Loss of institutional knowledge via the departure of the Board Chairperson.
📋 Key Facts
- Jeff Dykan (Class I director and Board Chairperson) notified the Board of his retirement on June 27, 2024.
- Mr. Dykan will continue to serve until the upcoming Annual Meeting of Shareholders.
- The departure is not due to any dispute or disagreement regarding company operations, policies, or practices.
- Joseph Turk has been appointed as the new chairperson, effective at the Annual Meeting.
- The Board does not intend to nominate a replacement candidate for Mr. Dykan's board seat.
ReWalk Robotics Ltd. filed an 8-K to furnish its quarterly financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings release and accompanying conference call.
📋 Key Facts
- Reported date: May 15, 2024
- Period covered: First quarter ended March 31, 2024
- The filing includes an earnings press release as Exhibit 99.1
- A conference call was scheduled for May 15, 2024, at 8:30 a.m. E.D.T. to discuss results.
ReWalk Robotics Ltd. announced the expansion of its Board of Directors through the appointment of Michael Swinford as a Class III director, effective April 18, 2024.
📋 Key Facts
- Board size increased from six (6) to seven (7) members.
- Michael Swinford appointed as a Class III director, serving until the 2026 annual meeting of shareholders.
- Mr. Swinford is an independent director according to SEC and Nasdaq standards.
- Swinford brings significant industry experience, having served as CEO of Numotion and previously as President and CEO of GE Healthcare Services ($5B business).
- Compensation for the new director will follow standard non-employee director compensation disclosed in the company's August 9, 2023 proxy statement.
ReWalk Robotics Ltd. has regained compliance with the Nasdaq Minimum Bid Price Requirement after maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
🚩 Red Flags
- Historical non-compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5550(a)(2)) indicates previous high volatility or significant downward pressure on share price.
📋 Key Facts
- The Company maintained a minimum closing bid price of at least $1.00 per share from March 15, 2024, to April 1, 2024.
- Nasdaq Listing Qualifications Hearings Department confirmed the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The matter regarding the minimum bid price requirement is now officially closed.
ReWalk Robotics Ltd. has furnished an investor presentation via its website under Regulation FD disclosure. This filing is a routine update intended for analysts and potential investors.
📋 Key Facts
- Filed on April 3, 2024.
- The company released an updated investor presentation slideshow (Exhibit 99.1).
- The information was furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
ReWalk Robotics Ltd. filed an 8-K to furnish its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of the earnings release and the scheduling of a related conference call.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: February 27, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
- A conference call to discuss results was scheduled for February 27, 2024, at 8:30 a.m. E.D.T.
ReWalk Robotics Ltd. announced a rebranding initiative, transitioning its business name to Lifeward™ effective January 29, 2024. The company's ordinary shares will trade under the new ticker symbol 'LFWD' on the Nasdaq Capital Market starting January 30, 2024.
📋 Key Facts
- Company is changing its name from ReWalk Robotics Ltd. to Lifeward™.
- Effective date of name change: January 29, 2024.
- New ticker symbol: LFWD (previously used/associated with the entity).
- Trading on Nasdaq Capital Market under new identity starts Jan 30, 2024.